Understanding the binding of inhibitors of matrix metalloproteinases by molecular docking, quantum mechanical calculations, molecular dynamics simulations, and a MMGBSA/MMBappl study by Singh, Tanya et al.
This journal is©The Royal Society of Chemistry 2015 Mol. BioSyst., 2015, 11, 1041--1051 | 1041
Cite this:Mol. BioSyst., 2015,
11, 1041
Understanding the binding of inhibitors of matrix
metalloproteinases by molecular docking, quantum
mechanical calculations, molecular dynamics
simulations, and a MMGBSA/MMBappl study†
Tanya Singh,ab Olayiwola Adedotun Adekoya*c and B. Jayaram*ab
Matrix metalloproteinases (MMPs) consist of a class of proteins required for normal tissue function. Their
over expression is associated with many disease states and hence the interest in MMPs as drug targets.
Almost all MMP inhibitors have been reported to fail in clinical trials due to lack of specificity. Zinc in the
binding site of metalloproteinases performs essential biological functions and contributes to the binding
affinity of inhibitors. The multiple possibilities for coordination geometry and the consequent charge on
the zinc atom indicate that parameters developed are not directly transferable across different families
of zinc metalloproteinases with different zinc coordination geometries, active sites and ligand
architectures which makes it difficult to evaluate metal–ligand interactions. In order to assist in drug
design endeavors for MMP targets, a computationally tractable pathway is presented, comprising docking
of small molecule inhibitors against the target MMPs, derivation of quantum mechanical charges on the
zinc ion in the active site and the amino acids coordinating with zinc including the inhibitor molecule,
molecular dynamics simulations on the docked ligand–MMP complexes and evaluation of binding affinities
of the ligand–MMP complexes via an accurate scoring function for zinc containing metalloprotein–ligand
complexes. The above pathway was applied to study the interaction of inhibitor Batimastat with MMPs,
which resulted in a high correlation between the predicted binding free energies and experiment, suggesting
the potential applicability of the pathway. We then proceeded to formulate a few design principles which
identify the key protein residues for generating molecules with high affinity and specificity against
each of the MMPs.
Introduction
MMPs as drug targets
Matrix metalloproteinases constitute a family of Ca2+ containing
and Zn2+ dependent proteins. The family consists of more than
26 proteinases in mammals. Based on their substrate specificity,
these are classified into collagenases (MMP-1, 8, 13 and 18),
gelatinases (MMP-2, and 9), stromelysins (MMP-3, 10, 11, and
27), matrilysins (MMP-7 and 26) and membrane-type (MT-MMP)
and other enzymes.1 The members contain a pre-domain
involved in enzyme secretion and a catalytic domain for the
activity of the enzyme. However, a C terminal domain in MMP-7,
MMP-27 and MMP-23 is involved in substrate recognition.
MMPs synthesized as inactive zymogens are activated through
the cleavage of their pro-domains by other enzymes.1 Their
enzymatic activity is regulated by their natural inhibitors viz.
tissue inhibitors of metalloproteinases (TIMPs).2,3 Expression of
these enzymes is responsible for several biological processes
such as embryonic development, signal regulation, wound
healing, angiogenesis, ovulation, uterine involution, bone
resorption and nerve growth.4–8 However a disturbance of this
leads to over-expression of MMPs followed by accelerated
matrix degradation mediating a number of pathological
processes by changing the structures of a large number of
substrates. The imbalance leads to several pathologies including
cancer, loss of cartilage in osteoarthritis, rheumatoid arthritis,
cardiovascular diseases, acute lung injury, peridontitis and many
others.9–15 The over expression of MMP-1, MMP-2, MMP-3,
MMP-8, MMP-9, MMP-13 has been implicated in various
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diseases like breast cancer,16 gastric cancer,17 peripheral nerve
injury,18–23 neuropathic pain,23 spinal cord injury,24–26 brain
injury,27–29 colorectal cancer,30 pathologic bone resorption,31
chronic wound,32 inflammation of the skin,33 inflammation of
the pulmonary tract,34 hypersensitivity,35 Alzheimer’s disease,36,37
Crohn’s disease,37 peridontitis.38 As a result, MMPs have become
drug targets of prime interest for finding effective inhibitors. The
number of available high resolution X-ray crystal structures of
MMP–inhibitor complexes has increased dramatically in recent
years helping in the design of potential inhibitors at an early lead
generation stage.39 Molecules exhibiting high affinity toward Zn2+
effectively would prevent the binding of the polypeptide to MMPs
and thus are considered to act as MMP inhibitors.40 Several Zn2+-
binding groups (ZBGs) have been reported: the hydroxamates,
reverse hydroxamates, carboxylates, hydroxyureas, hydrazides,
phosphinates, sulfones, and sulfonylhydrazides of which the
hydroxamates appear to be the most potent ones among them.1
Many broad spectrum ZBG-containing small molecule inhibitors
from different pharmaceutical companies have also entered clinical
trials for cancer, rheumatoid arthritis, and osteoarthritis.41,42 These
broad-spectrum MMP inhibitors include hydroxamate-based
Marimastat, Batimastat, Ilomastat, Prinomastat, Solimastat,
Tanomastat, MMI-270, Trocade, Periomastat and Metamastat.
Nearly all of these MMP inhibitors have failed in clinical trials
due to lack of specificity against a given class of MMPs1 posing a
challenge to rational drug design of specific MMP inhibitors. Zinc
is commonly found to be four-coordinated with a tetrahedral
geometry; five and six coordinated geometries are also observed in
zinc metalloproteinases, playing an important role in metal–ligand
binding.41 The geometries of zinc in different protein–ligand
complexes have been illustrated previously.43 Computational
docking and prediction of binding affinities of metalloproteinase
inhibitors to MMPs remains a challenge due to the multiple
coordination geometries of zinc and lack of appropriate force
field parameters to model the metal–ligand interactions.44
Addressing these challenges, we combine in the current study,
molecular docking, quantum mechanical charge derivation of the
Zn atom in the binding site followed by molecular dynamics
simulations on MMP–inhibitor complexes, and a post facto analysis
of the MD trajectories to evaluate the binding free energies
associated with MMP–inhibitor complexation. The ability to effec-
tively predict the binding modes and affinities of small molecule
inhibitors45 of these zinc containing enzymes computationally can
be of utmost importance in designing very selective clinically
relevant inhibitors. Our study has resulted in the identification of
key residues in different MMPs and formulation of a few design
principles and further a set of new molecules with high affinity and
specificity for each of the MMPs. These are described below.
Methodology
Batimastat is a broad spectrum MMP inhibitor reported to have
IC50 values (in nM) of 10, 4, 20, 10, 1 and 3 against MMP-1,
MMP-2, MMP-3, MMP-8, MMP-9, and MMP-13 respectively.1
A docking and scoring study of Batimastat against these classes
of MMPs was performed. A flowchart describing the computa-
tional pathway followed for a systematic analysis of the binding
of MMP inhibitors to the target protein in the current study is
shown in Fig. 1.
Docking the inhibitor in the target protein
The three-dimensional structures of MMPs were adapted from
RCSB with PDB ids 2TCL, 1HOV, 1BIW, 1MNC, 1GKC, 456C
corresponding to MMP-1, MMP-2, MMP-3, MMP-8, MMP-9 and
MMP-13 respectively.2 The zinc ion occurs in 4 or 5 coordinate
geometry with the protein and the ligand atoms which are lying
within a distance of 1.8 Å to 2.7 Å. A vast majority of MMP
inhibitors chelate the catalytic zinc ion either in monodentate
or bidentate fashion. These inhibitors replace the water molecule
and coordinately bind to the zinc. Thus, the crystallographic water
was removed from the protein42,46–48 before performing the
docking studies. Hydrogens were added49 and the correct force
field parameters were assigned to the protein.43 The protona-
tion states of the histidine residue were adjusted according to
the hydrogen bond network.50 The basic amino acids were
protonated and the carboxylic groups were kept deprotonated.
The coordinates of the Batimastat–MMP complexes are not
reported. The inhibitor molecule Batimastat was modeled1
maintaining the ionization states mentioned in the literature.
The overall formal charge42 on the Batimastat was 1. The
molecule was then geometry optimized through the AM1
procedure followed by calculation of partial charges of the
ligand by the AM1-BCC procedure.51 GAFF force field para-
meters52 were used to assign atom types, bond angles, dihedral
and van der Waals parameters53 to the inhibitor molecule. The
target protein–ligand complex and the inhibitor molecule were
given as input to Sanjeevini54 software suite for docking and
scoring studies. Sanjeevini is a freely accessible web server for
protein and DNA targeted lead molecule discovery. The web
server builds in several features including detection of the
binding site in the target protein, scanning against a library
of million compounds to identify hit molecules against a target
protein, all atom based docking and scoring module and
various other utilities to design molecules with desired affinity
and specificity. The docking and scoring module of Sanjeevini
has been previously validated on a large dataset of 335 protein–
DNA drug targets for inhibitors with known crystal structures
and known experimental binding free energies.54 The protein
targets consist of zinc containing metallo proteinases as well.
The predicted binding free energy of the top ranked docked
structures given as an output when compared with the experi-
mental binding free energies gave a correlation coefficient r of
0.83. The root mean square deviation of the top ranked docked
structure against the crystal structure was within 2 Å with 90%
accuracy. The docking and scoring module of Sanjeevini was
validated on matrix metalloproteinases with known inhibitors.
A correlation coefficient r of 0.82 and R2 = 0.68 was obtained
between experimental and predicted binding free energies of
the top ranked docked structure as shown in Fig. 2. The
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top ranked docked structure against the crystal structure are
given in Table S1 (ESI†).
The docking module of Sanjeevini55,56 docks the ligand
molecule in the binding site and generates several (B103)
configurations via a six-dimensional rigid body Monte
Carlo methodology resulting in many ligand configurations
which are scored based on the scoring function in-built in
Sanjeevini.43,57–59
Derivation of partial atomic charges on the docked ligand and
the zinc ion, and the protein atoms
In the zinc containing metalloproteinases the ligand molecule
is bonded with one or two co-ordinate bonds with the zinc ion
due to which the total formal charge on the zinc is always less
than +2 due to the charge transfer occurring between the amino
acids and the ligand molecule coordinately bonded to the zinc
ion. An accurate modelling of a large biomolecular system by
the quantum mechanical method is computationally very
expensive. However, quantum mechanical calculations on a
small part of the system (active site of a protein) are affordable
which could lead to insufficient descriptions. The semiempi-
rical methods have successfully handled thousands of atoms
but are not accurate in modelling systems with transition
metals. The hybrid QM/MM method pioneered by Warshel
and Levitt60 is successful in providing solutions for the complex
systems. The ONIOM (Own N layer Integrated molecular Orbital
molecular mechanics) method is successfully applied to metal-
loenzymes. In a similar approach, where for the smaller region
that is on the zinc binding moiety comprising the protein
residues within the coordinate bond distance (r2.7 Å) of the
zinc ion, the ligand and the zinc ion were subjected to HF/6-
31G* ab initio calculations through Gaussian software61 suite
followed by RESP fitting on the resultant electrostatic potentials
to obtain partial atomic charges on the ligand and the zinc ion.
Fig. 2 Correlation between experimental binding free energies and pre-
dicted binding free energies (in kcal mol1) for the binding of known MMP
inhibitors.
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For the calculations, the protein residues within the coordinate
bond distance were deprotonated and the net charge on the
zinc binding motif was calculated which was a sum of the
formal charge on each amino acid residue, formal charge on
the ligand and +2 charge on the zinc ion.43 van der Waals para-
meters for the zinc ion were adapted from the work of Stote and
Karplus62 [s = 1.95 Å and e = 0.25 kcal] together with GAFF force
field parameters for the ligand molecule.51 The AntechAMBER49
module of AMBER was used to assign the bonded and the
nonbonded parameters to the ligand atoms. The protein atoms
were assigned RESP derived partial atomic charges, van der
Waals and bonded parameters using the AMBER force field.43
The charges on the docked-MMP complexes are available at the
following link http://scfbio-iitd.res.in/sanjeevini/MMP.jsp.
Accounting for protein and ligand flexibility through molecular
dynamics simulations
The protein–inhibitor complexes were subjected to molecular
dynamics simulations to factor in the flexibility/dynamics of the
ligand and the active site residues of the target along with explicit
solvent and salt effects.63 Simulations were carried out with
periodic boundary conditions using AMBER suite of programs.49
11 Na+ ions were added to MMP-2 and MMP-3 inhibitor
complexes, 12 Na+ ions to MMP-1, MMP-8, and MMP-9 inhibitor
complexes and 7 Na+ ions to the MMP-13 inhibitor complex to
ensure electroneutrality of the protein–ligand complex being
simulated. The complex was then solvated with a layer of water
8 Å thick. Water was modeled using the TIP4PEW parameters.64
To maintain the orientation of the zinc-chelating histidine resi-
dues and to prevent the escape of the zinc atoms into the solvent,
a restraint was applied on the distances defined by zinc and the
nitrogen atoms of the histidine residue. After the initial prepara-
tion of the docked complexes the solvent was subjected to an
initial minimization followed by the minimization of the solute–
solvent system. A slow heating to 300 K was performed at constant
volume over a period of 100 ps using harmonic restraints of
25 kcal mol1 Å2 on the solute atoms. These restraints were
then slowly relaxed from 5 to 1 kcal mol1 Å2 in five segments of
1000 steps of energy minimization and 50 ps of equilibration with
a constant temperature of 300 K and a pressure of 1 bar via the
Berendsen algorithm65 with a coupling constant of 0.2 ps for
both parameters. Finally a 50 ps equilibration with a restraint of
0.5 kcal mol1 Å2 and a 50 ps of unrestrained equilibration was
performed. Molecular dynamics simulation was then carried out
for 100 ns at constant temperature and pressure conditions using
Berendsen algorithm with a coupling constant of 5 ps. In all, six
molecular dynamics simulation66 runs were performed corre-
sponding to the binding of Batimastat with MMP-1, MMP-2,
MMP-3, MMP-8, MMP-9, and MMP-13. RMSD versus time plots
were monitored for all the simulation runs to ensure the stability
of the docked complexes.
Post molecular dynamics simulation preparation of the docked
complexes
At the end of molecular dynamics simulations, 100 structures
were obtained from each of the six trajectories at equal intervals
from the last 40 ns trajectory file and prepared for binding
free energy estimates of the protein–ligand complexes using
Bappl-Z43 scoring function. The approach is parameterized
within the additivity approximation where the net free energy
change is treated as a sum of a comprehensive set of individual
energy-component contributions. The components are estimated
in a force field compatible manner. The equation for the estimation
of free energy change upon binding is:
DG ¼ aEel þ bEvdW þ
X22
A¼1
sADALSA þ l DSCRð Þ þ d (1)
This methodology overcomes the limitations inherent in single
point calculations (studies on energy minimized structures)
by subjecting the systems to configurational averaging via mole-
cular dynamic simulations. The above BapplZ scoring function
validated thoroughly the earlier43 captures of the theoretical
rigor of MMGBSA/MMPBSA67–71 methodology as well as rapidity
of empirical/knowledge based methods.43,72,73 Each component
in eqn (1) is described below.
Eel electrostatic term includes interactions between protein with
the ligand atoms and the zinc ion with the rest of the complex. The
interactions are calculated from Coulomb’s law with a sigmoidal
dielectric function for solvent screening to incorporate the desolva-
tion electrostatics implicitly.43,57,72 A non-bonded model from the
work of Stote and Karplus62 has been adopted to model the
electrostatics interactions of zinc with the rest of the complex.
EvdW van der Waals term includes direct van der Waals between
protein with ligand atoms and the zinc ion with the rest of the
complex. The interactions were modeled using a (12,6) Lennard-
Jones potential.43 Again the work of Stote and Karplus was adopted
to model the van der Waals interactions for the zinc ion.
sADALSA hydrophobic component captures mainly the non
electrostatic component of desolvation using the modified version
of the Eisenberg–Mclachlan model where the atom types in the
AMBER force field for proteins and small molecules have been
combined into a set of 22 atom types43 to ensure transferability of
parameters to other biomolecular systems. DALSA in the above
eqn (1) represents the net loss in surface area for an atom type.
The DSCR term represents the loss in conformational entropy of
protein side chains upon the binding of ligand to the protein.43
Computational details of the above work have been explained
earlier.43 The DG1 from the above equation is calculated for the
single point system representing each snapshot of the structures
obtained over the last 40 ns trajectory file and a block averaging
is done to obtain the average binding free energy values.
Results and discussion
In the zinc containing metalloprotein–ligand complexes, the
ligand is coordinately bonded to the zinc ion with one or two
coordinate bonds. Sanjeevini gives as output four docked struc-
tures representing energetically favorable poses of the ligand
molecule in the binding site, out of their several configurations
based on energy ranking defined by the scoring function. From

























































































This journal is©The Royal Society of Chemistry 2015 Mol. BioSyst., 2015, 11, 1041--1051 | 1045
hydroxamate group showed a chelation to the zinc ion was
collected. The RMSD vs. time plots shown in Fig. S1 to S6 (ESI†)
attest to the stability of the docked complexes. Further, structures
obtained from each of the molecular dynamics trajectories were
processed through BapplZ scoring function and the average
binding energies were calculated for Batimastat binding to different
MMPs. Fig. S7 to S12 (ESI†) show the convergence of the binding
energy values. We further plotted a correlation between the experi-
mental and predicted binding free energies for Batimastat binding
to different MMPs (Fig. 3). An efficient docking algorithm, a correct
charge assignment protocol, a rigorous molecular dynamics simula-
tion study and an accurate scoring function contribute to structural,
dynamic and thermodynamic rationalization of experimental
inhibition data, as evident from a high correlation coefficient
between the experimental and predicted binding free energies
shown in Fig. 3, thus demonstrating the efficiency of the computa-
tional pathway followed. The molecular dynamics simulation
studies incorporated the structural and dynamic effects of the
ligand which cannot be disclosed by docking studies alone.
For Batimastat the inhibitor was considerably less specific
against any MMP. One of the major reasons for the lack of efficacy
of MMP inhibitors is due to the reason that they are broad
spectrum. Design of specific MMP inhibitors is thus interesting
and challenging. In MMPs, in addition to the catalytic site, there
are other sites designated as S1, S2, S3 and S10, S20 S30, shown1 in
Fig. 4, along with the catalytic region. The main site for substrate
recognition is the specificity pocket S10 as the site differs in shape
and size among different MMPs. Moreover, due to flexibility of the
MMP binding pockets74–78 predicting the binding free energies in
silico has been difficult. Though structural information from the
X-ray structures can be used to design inhibitors with high affinity
and selectivity towards a given MMP, the flexibility of the MMP
binding pockets limits an accurate estimation of binding free
energies against a given MMP.
With the above concerns in focus, we further extended our
study to the design of specific inhibitors against diverse MMPs
dealt with above. A sequence alignment was performed on the
MMPs using Clustal W program.79 The specificity loop regions
of different MMPs are shown in Fig. 5. While designing
inhibitor molecules, amino acids showing a variation in the
specificity loop region need to be considered to take care of the
specificity issue.
Some design principles for MMP inhibitors
We designed a few specific molecules against different MMPs
with a special focus on MMP-2, MMP-3, MMP-8, MMP-9 and
MMP-13 whose over expression is associated with various
diseases. The molecules were designed with the main goal to fit
in the S10 groove adjacent to the catalytic site of the MMPs to
come up with specific hit molecules. The docked structures were
subjected to molecular dynamics simulations using the protocol
detailed in the methodology section for 10 ns to consider the
flexibility/dynamics of the ligand and the active site residues of
the target along with the explicit solvent, salt effects and also to
account for the induced fit effects. After running the simulations,
the docked structures obtained during the last four ns simulation
runs were subjected to BapplZ calculation43 and an average
binding free energy was calculated. To check on the affinity versus
specificity of the molecules designed against each class of MMP, a
cross docking study was also performed. Table 1 shows the
potential ligands obtained against different MMPs and an affinity
versus specificity matrix for the molecules designed.
The scaffolds of the molecules designed are shown in Fig. 6–10
against MMP-2, MMP-3, MMP-8, MMP9 and MMP-13 respectively.
The nomenclature to the designed molecules was given as per the
MMP target for which it was designed. Molecule 2, molecule 3,
molecule 8, molecule 9 and molecule 13 correspond to MMP-2,
MMP-3, MMP-8, MMP-9 and MMP-13, respectively.
Fig. 3 Correlation between experimental pIC50 and predicted binding
free energies (in kcal mol1) for the binding of Batimastat with MMP-1,
MMP-2, MMP-3, MMP-8, MMP-9, MMP-13.
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There is considerable variation in the amino acids defining
the shape and size of the S10 site. The MMP-1 has a shallow S10
pocket, MMP-2, MMP-8 and MMP-9 have intermediate depths
and the MMP-3 and MMP-13 have deep S10 pockets as can be
seen in Fig. S13–S17 (ESI†). In MMP-1, Arg 114 at the start of
the catalytic helix makes the S10 site very shallow, providing
scope for designing molecules specific for other MMPs and not
against MMP-1, as they are reported to be involved in musculo-
skeletal pains on getting inhibited by broad spectrum MMP
inhibitors.43 The RASPD module of Sanjeevini54 was used to
obtain the initial hit molecules against the target MMPs from a
million molecule database of small organic molecules (public
version of zinc database80). The module sets up a QSAR type
equation to find complementarity between the physico-chemical
properties of the binding site of the protein and the candidate
ligand molecule to estimate a binding energy between them. The
molecule with ZINCID 20601870 (IUPAC name: 5-(2-furyl)-N-[1-
[2-(1-piperidyl)ethyl]benzimidazol-2-yl]-7-(trifluoromethyl)pyr-
azolo[1,5-a]pyrimidi) was obtained as the top hit for all the
MMPs as the binding site of the MMPs are very homologous to
each other. Our attention was engaged by the presence of the
carbonyl group which can show potential interaction with the
zinc and the aromatic groups with suitable curvatures to show
interactions with the S1 0 site. However, since the S10 site varies
in the amino acid sequence and overall architecture, the
starting scaffold of the molecule was modified through a
structure based design approach targeting the S1 0 site along
with the catalytic/binding site to bring in affinity as well as
specificity of the molecules designed for each class of MMPs.
Thus, the main focus while designing the inhibitors for the
respective MMPs was to optimize the length of the molecule
designed according to the differences in the depth of the S10
pocket for different MMP subtypes. The fragment of the mole-
cule penetrating the S10 site is referred to as the P10 fragment.1
An inhibitor molecule that can show a chelation with the
catalytic zinc ion and protrude into the S10 site of MMP-2, which
is lined by the hydrophobic side chains81 of Leu-83, Phe-115,
Leu-116, Val-117, Ile-141 and Phe-148, was designed. We focused
on designing an expected fragment targeting the S10 site, which
was elongated and had a hydrophobic group along with a zinc
chelating group. The inhibitor molecule 2, designed for MMP-2
fitted well in the S10 hydrophobic pocket facilitated by the long
hydrophobic chains and showed electrostatic interaction with
the zinc ion facilitated by the oxygen atom as shown in Fig. S13
(ESI†). During the molecular dynamics run on the MMP-2
inhibitor docked complex, conformational changes occurred
suggesting the aromatic ring of Phe-148 moving towards the
inhibitor molecule to make interactions and the Arg-149 rotating
Fig. 5 Sequence alignment of MMPs. The highlighted region shows the amino acids lying in the specificity loop region.
Table 1 Affinity versus specificity matrix of the designed molecules (the
binding energies predicted by Sanjeevini web server are reported in kcal mol1)
Molecule
MMP Molecule 2 Molecule 3 Molecule 8 Molecule 9 Molecule 13
MMP1 2.05 10.93 3.44 9.52 10.92
MMP2 10.67 7.09 0.68 8.18 9.748
MMP3 7.09 16.64 9.5 12.94 9.84
MMP8 6.25 0.82 10.45 12.09 10.42
MMP9 7.89 9.64 1.15 15.55 8.71
MMP13 1.21 11.26 1.07 8.12 15.09
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to accommodate changes in Phe-148 (Fig. S13, ESI†). The above
study suggests that molecules with a longer alkyl chain protruding
towards the cleft formed by the movement of Phe-148 show better
affinity against MMP-2. Moreover, while designing molecule 2 the
structure and amino acid sequence of the other MMPs were
critically examined to come up with a molecule showing high
affinity as well as specificity against MMP-2. The S10 loop of
MMP-2 is two amino acids shorter than MMP-8 due to which
there is an extra hump at the bottom of the loop before conver-
ging with MMP-2. The non-conservative substitution Thr-143 in
MMP-2 or Ala-240 in MMP-8 and Thr-145 in MMP-2 or Arg-243 in
MMP-8 throw in differences in the inhibitory pattern of MMP-2
and MMP-8. In the uninhibited MMP-882 residue Arg-243
obstructs the S10 groove due to which molecule 2 with a longer
alkyl chain failed to fit in the S10 groove of MMP-8. Similarly,
inhibitors with long substituents protruding into the S10 inhibit
MMP-2 (Fig. S13, ESI†) but fail to inhibit MMP-9 due to occlusion
by1,83 Arg 424 (Fig. S16, ESI†). A structural alignment of MMP-2
and MMP-9 shows an equivalent Pro-429 and Pro-430 in MMP-9
corresponding to Phe-148 and Arg-149 in MMP-2 which does not
offer enough conformational flexibility to accommodate mole-
cules with longer alkyl chains in MMP-9. Molecule 2 showed
lesser affinity against MMP-3 and MMP-13 due to a longer S10
groove of the same as evident from Table 1 making the molecule
specific to MMP-2.
The S10 channel of MMP-3 includes Leu-197, Val-198,
His-201, Leu-218, Tyr-220, along with S10 wall residues as
highlighted in Fig. 5. While designing molecule 3 the length
of the P10 group was increased in comparison to molecule 2 to
make it more specific towards MMPs with a deeper S10 site as
in MMP-3 in comparison with MMP-1, MMP-2, MMP-8 and
MMP-9. A carboxylate group was introduced at the terminal
towards the floor of the S10 site at the end of the hydrophobic
Fig. 7 Scaffold of molecule 3 designed against MMP-3.
Fig. 8 Scaffold of molecule 8 designed against MMP-8.
Fig. 9 Scaffold of molecule 9 designed against MMP-9.
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chain which could show hydrogen bonding interaction with
Arg 233 in MMP-3. A possible alternative would have been
an electropositive group showing interaction with Asp-228.
However, a carboxylate group interacting with arginine can be
considered to have more conformational flexibility than Asp-
228. This interaction would maintain a tight fitting of molecule
3 in the S10 site along with the electrostatic interaction of the
N1 atom of molecule 3 with the zinc ion (Fig. S14, ESI†). The
docked complex was subjected to molecular dynamics simula-
tions. The Arg-233 (Fig. S14, ESI†) during simulation contri-
buted to an induced fit interaction towards the carboxylate
group of molecule 3 along with a good hydrophobic fit in the
S10 groove and an electrostatic interaction with the zinc ion.
A structural superimposition of MMP-3 and MMP-13 shows an
equivalent Met-232 to Arg-233 in MMP-13 providing a scope for
designing specific inhibitors against MMP-3 (Table 1).
Molecule 8 was designed to show high affinity against
MMP-8. The key residues in MMP-8 to bring in affinity as well
as specificity can be accredited to Arg-243 and Asn-239
(Fig. S15, ESI†). The orientation of the carboxylate group in
molecule 8, which can interact with Arg-243 and an electro-
negative fluorine atom to show hydrogen bonding with the
Asn-239 (Fig. S15, ESI†), was designed along with an N1 atom of
molecule 8 chelating with the zinc ion. These residues vary
sequentially as well as structurally in other MMPs (Fig. 5) in the
S10 region. The unique conformation of molecule 8 resulting
due to the carboxylate groups and the trifluoromethyl group at
the terminal of molecule 8 made the above residues acquies-
cent to interact favorably with MMP-8 (Fig. S15, ESI†) and
poorly with other MMPs due to steric clashes.
The S10 pocket of MMP-9 consists of Asp-185–Leu-188 and
Pro-421–Tyr-423. The S10 wall comprises1,84,85 Leu-188, Leu-397,
Val-398, His-401, Leu-418, Met-422 and Tyr-423. The catalytic
sites of MMP-2 and MMP-9 show high degree of similarity but
with variations in the S10 loop region. The orientation of the
equivalent residues Arg424 and Thr 426 in the S10 pocket of
MMP-9 and MMP-2 respectively causes difference in the overall
shape and size of the S10 pocket. Inhibitors with long substi-
tuents protruding into the S10 inhibit MMP-2 (Fig. S13, ESI†)
but fail to inhibit MMP-9 due to occlusion by Arg-424 and vice
versa (Fig. S16, ESI†). Molecule 9 designed specifically to bind
MMP-9 showed lesser binding to MMP-2, MMP-3, MMP-8 and
MMP-13 as the molecule did not make a way inside the groove
due to steric clashes and failed to show favorable interaction
with the equivalent residues in the S10 region. Molecule 9
comprised of three sub-fragments. The fragment with a zinc
chelating N atom (Fig. S16, ESI†), and a P10 fragment with a
carboxylate group at the terminal showing hydrogen bonding
with Arg 424 with an aromatic linker carrying a trifluoromethyl
group maintains a good fit of molecule 9 at the catalytic and S10
sub site of MMP-9. Molecule 2, molecule 9 and molecule 8
showed lesser affinity against MMP-3 and MMP-13 due to a
longer S10 groove of the same as evident from Table 1.
The specificity loop of MMP-13 shows flexibility86 when it is
in contact with inhibitors which is critical for binding. The
meticulous conformation of S10 loop defines its shape and size.
The conformational restriction appears obvious for the other
MMPs with shorter specificity loop regions in MMP-1, MMP-2,
MMP-8 and MMP-9. However, for MMPs with similar or longer
specificity loops as in MMP-3, the nature of the residues in the
specificity loop region (Fig. 5) in MMP-13 and their conforma-
tions are the structural determinants for high MMP-13 selectivity.
Molecule 13 (Fig. S17, ESI†) was designed to show specificity
against MMP-13 by fitting well in the S10 groove with a hydrogen
bond interaction with Thr-245 and Thr-247 in comparison to
MMP-3 which has an equivalent Leu-226 which restricts confor-
mational flexibility to the equivalent residues. Gly-248 in MMP-13
provides conformational flexibility in this position allowing the
neighboring residues Thr-245, Tyr-246, Thr-247 to interact with
the inhibitor molecules by providing room for induced fit inter-
action with the ligand molecule.
The fragments added or modified in the starting hit mole-
cule obtained from the RASPD module, was not inspired from
any molecule already in use for the MMPs but was designed to
come up with important pharmocophoric suggestions for each
MMPs studied. The functional groups/fragments added were
varied according to the length of the S10 site and the key
residues discussed in different MMPs in order to account for
the specificity and affinity of the designed molecules. The
quality of chemical collection increases if the compounds have
drug like properties. A well known rule of five developed by
Lipinski has been a milestone of filtering techniques. The rule
identifies compounds that are likely to exhibit good bioavail-
ability. The molecular weight, log P, number of hydrogen bond
donor and number of hydrogen bond acceptor atoms were
calculated using the Lipinski module of Sanjeevini web server.
The values are reported in Table S3 (ESI†) signifying the drug
like properties of the molecules designed. Additionally, synthe-
sizability of the proposed molecules albeit with a large number
of synthetic steps has been confirmed. Further synthesis of
these molecules or similar molecules satisfying the phramaco-
phoric/geometric criteria to interact with the key residues
highlighted in different MMPs and further in vitro experimental
test is conceivable in near future.
Free energy analyses
The semi empirical methodology (BapplZ/MD) adopted has
been reported to accurately predict the electrostatics, van der
Waals, hydrophobicity and loss in conformational entropy of
protein side chains upon ligand binding and an approach to
model the interactions of zinc with the other atoms. The MMPs
belong to a highly flexible class of proteins especially the S10
site which is considered to bring in specificity for the hit
molecules while binding against different MMPs. To fully
understand the role of structural adaptation in cases where
flexibility could be an important issue i.e. when significant
structural changes in the target and the ligand are expected
upon binding, one must perform an additional initial state
(before binding) versus the final state (after binding) analysis.
Thus a post facto MMGBSA (modified generalized Born solvent
accessibility) analysis of the trajectories of the bound protein–
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performed to further understand the energetic consequences of
flexibility and structural adaptation.74,75 Here, the net binding
free energy is considered to be a sum of the free energy changes
due to rotational translational entropy losses, deformation or
adaptation expense, van der Waals interactions between the
protein and ligand, and net electrostatics and cavitation term.
The net electrostatics includes the Coulomb interaction
between protein and the ligand and the electrostatic compo-
nent of solvation. The thermodynamic cycle to obtain the
standard free energy of complex formation comprising the
above energy components has been discussed in Fig. 2 of
Jayaram et al. The modified MMGBSA method was applied to
the docked structures collected over the last 4 ns trajectories for
the molecules designed and an averaging was done to study the
various components contributing towards binding free energy.
The average binding free energy and the various components
contributing towards the binding free energy for the docked
molecule 2, molecule 3, molecule 8, molecule 9 and molecule
13 against their respective MMPs have been shown in Fig. S18
(ESI†). The direct electrostatics, van der Waals interactions
and the hydrophobic interactions favour the binding of protein
and the designed molecules. The electrostatic and the van der
Waals component of desolvation, the deformation and the
rotational translational entropy disfavour complexation. Over-
all, the MMGBSA analyses indicate that despite the flexibility of
the target proteins, the designed molecules retain their binding
affinity. Different terms or descriptors are generally employed
in any scoring function to obtain a binding free energy estimate
of the docked protein–ligand complexes. Both empirical (BapplZ)
and the MMSGSA methodologies have been adopted in the
current work for addressing different components of binding
generating a hit molecule with high affinity and specificity
against the target MMPs. While the overall picture remains
similar to empirical energy function analyses, the overall binding
free energies being negative suggesting a hit against the corres-
ponding MMPs, the MD trajectory analyses take into account
structural adaptation of the interacting molecules and role of
solvation/desolvation effects in binding more explicitly. The
magnitudes of the components provide a good indicator to the
order of importance of the energy components favourable to
binding and prove valuable in design efforts.
The docking and scoring methodology adopted in the
current study including a QM/MM based method to derive
charges on the docked protein–ligand complex was compared
with some of the previously reported work in the literature
where a binding free energy calculation was done using
Autodock software on 16 known inhibitors87 of MMPs. The
predicted binding free energies of the top ranked docked
structure reported by Autodock and the Sanjeevini software
are shown in Table S2 (ESI†). A correlation coefficient r of
0.59 and 0.87 were obtained by Autodock and Sanjeevini soft-
ware respectively between the experimental and the predicted
binding free energies. Molecules showing activity against some
of these MMPs like MMP-9 have been reported using pharma-
cophore based approaches with a focus on the S1 subsite.88 In
the present study, a protein structure based approach is used to
design inhibitors against the five classes of MMPs. Selectivity
being the major issue, a protein structure based approach using
a robust and high accuracy docking and scoring methodology
followed by a molecular dynamics simulation study has an edge
in comparison to the pharmacophore based design of MMP
inhibitors. Moreover a comparison between the S10 site followed
by a cross docking and scoring approach (Table 1) between
different MMPs as carried out in the present study versus a
consideration of the S1 site alone of a particular MMP as done
previously (Kalva, Azhagiya et al. 201488) can help in the design
of more specific inhibitors against each class of the MMPs.
Conclusions
Rational design of specific MMP inhibitors has been challen-
ging due to various isomorphs belonging to the above family of
enzymes having very flexible binding sites. The docking and
scoring module of Sanjeevini used in the current work was
successful in giving a high correlation between the experi-
mental and predicted binding energy for MMP inhibitors with
known crystal structures. A high accuracy docking and scoring
methodology, an accurate QM/MM approach to calculate charge
on the docked protein ligand complex followed by molecular
dynamics simulations, gave a high correlation between the experi-
mental and predicted binding energy for a known MMP inhibitor
(Batimastat) with an unknown crystal structure. An MMGBSA
analysis accounts for various computational challenges like receptor
flexibility and induced fit effects. Further, a comparison between the
S10 site followed by a cross docking and scoring approach (Table 1)
between different MMPs as carried out in the present study versus a
consideration of the S1 site alone of a particular MMP can help in
the design of more specific inhibitors against each class of MMPs.
Certain key residues are identified in S10 sites of different MMPs to
design molecules with suitable fragments to hold a stable coordina-
tion with the zinc ion and a proper fit in the S10 site to address the
affinity and specificity issues.
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